RGEN241220C190000
- 0.65
- 0.000.00%
Repligen Newsroom
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report
RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)
Several Factors Lifted Repligen Corporation (RGEN) in Q3
Repligen Launches Novel AVIPure DsRNA Resin in OPUS Pre-packed Columns
RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating
Insider Sale: Director at $RGEN (RGEN) Sells 24,246 Shares
Repligen(RGEN.US) Director Sells US$3.39 Million in Common Stock
Express News | Form 144 | Repligen(RGEN.US) Insider Proposes to Sell 3.39 Million in Common Stocks
Repligen | 10-Q: Q3 2024 Earnings Report
Repligen | 10-K/A: Annual report (Amendment)
Repligen | 10-Q/A: Quarterly report (Amendment)
Repligen Analyst Ratings
Wolfe Research Initiates Repligen(RGEN.US) With Hold Rating
Repligen Initiated With a Peer Perform at Wolfe Research
Express News | Repligen Corp : UBS Raises Target Price to $190 From $185
Stifel Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $207
Benchmark Co. Maintains Repligen(RGEN.US) With Hold Rating
Repligen (RGEN) Receives a Hold From Benchmark Co.
RBC Capital Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $205